Web Desc
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies
Organizer(s): Christian Klein, Mark S. Cragg and Germaine Fuh
Date: April 07 - 11, 2019
Location: Beaver Run Resort, Breckenridge, CO, USA
Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG and Roche
Summary of Meeting:
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.
Scholarship Deadline: December 11 2018
Discounted Abstract Deadline: December 11 2018
Abstract Deadline: January 9 2019
Discounted Registration Deadline: February 6 2019
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AbbVie Inc.Bioverativ TherapeuticsImmunoGen, Inc.Incyte CorporationMerck & Co., Inc.MorphoSys AGRoche
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

CytomX Therapeutics, Inc.

Denali Therapeutics Inc.

Genmab B.V.

ImmunoGen, Inc.

Lundbeck

NovImmune SA

Regeneron Pharmaceuticals, Inc.

Roche

Xencor, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI145248-01
Funding for this conference was made possible (in part) by 1R13AI145248-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, April 07 | 4:00PM - 8:00PM
Arrival and Registration
Room: Colorado Ballroom Foyer


Sunday, April 07 | 6:00PM - 8:00PM
Welcome Mixer
Room: Colorado Ballroom Foyer
No registration fees are used to fund alcohol served at this function.

Monday, April 08 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Monday, April 08 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Colorado Ballroom

Speaker 1 of 4
* Christian Klein, Roche, Switzerland

Monday, April 08 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Colorado Ballroom

Speaker 2 of 4
George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA
Target Identification and Developing Antibodies for Clinical Application

Monday, April 08 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Colorado Ballroom

Speaker 3 of 4
Jennifer R. Cochran, Stanford University, USA
Emerging Strategies for Developing Next-Generation Protein Therapeutics

Monday, April 08 | 8:00AM - 9:30AM
Welcome and Keynote Session
Room: Colorado Ballroom


Coffee Break

Monday, April 08 | 9:50AM - 11:45AM
Mechanisms of Action for Depleting Antibodies
Room: Colorado Ballroom

Speaker 1 of 6
* Janine Schuurman, Genmab B.V., Netherlands

Monday, April 08 | 9:50AM - 11:45AM
Mechanisms of Action for Depleting Antibodies
Room: Colorado Ballroom

Speaker 2 of 6
Mark S. Cragg, University of Southampton, UK
Targeting B Cells with Antibodies: From Oncology to Autoimmunity

Monday, April 08 | 9:50AM - 11:45AM
Mechanisms of Action for Depleting Antibodies
Room: Colorado Ballroom

Speaker 3 of 6
Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany
The Where, When, and How: Organ Specific Pathways of Cytotoxic IgG Activity

Monday, April 08 | 9:50AM - 11:45AM
Mechanisms of Action for Depleting Antibodies
Room: Colorado Ballroom

Speaker 4 of 6
Annalee W. Nguyen, University of Texas at Austin, USA
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment

Monday, April 08 | 9:50AM - 11:45AM
Mechanisms of Action for Depleting Antibodies
Room: Colorado Ballroom

Speaker 5 of 6
Polina Weitzenfeld, Rockefeller University, USA
Short Talk: Antibody Targeting of Carbohydrate-Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance

Monday, April 08 | 9:50AM - 11:45AM
Mechanisms of Action for Depleting Antibodies
Room: Colorado Ballroom

Speaker 6 of 6
Michael M. Schmidt, Compass Therapeutics, USA
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain-Based Bispecific Antibodies

Monday, April 08 | 11:45AM - 5:00PM
On Own for Lunch


Monday, April 08 | 11:45AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Monday, April 08 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom


Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 1 of 9
* Christian Klein, Roche, Switzerland

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 2 of 9
Starlynn Clarke, TeneoBio Inc., USA
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 3 of 9
Lynn A. Kamen, Genentech, Inc., USA
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 4 of 9
Jason Lajoie, Compass Therapeutics, USA
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 5 of 9
Ahlam Qerqez, University of Texas at Austin, USA
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 6 of 9
Diana Darowski, Roche Gylcart AG, Switzerland
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 7 of 9
Koen Wagner, AIMM Therapeutics, Netherlands
AT1413 T-Cell Engager Activity Is Determined by T-Cell Engager Format Valency

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 8 of 9
Phillip Liu, Sound Biologics, USA
Development of MabPair Technology, a Novel Platform for Producing Bifunctional Antibody Products

Monday, April 08 | 2:30PM - 4:30PM
Workshop 1: Engineering (Bispecific) Antibodies
Room: Colorado Ballroom

Speaker 9 of 9
Brandy R. White, California State University, Fresno, USA
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer

Monday, April 08 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Monday, April 08 | 5:00PM - 7:00PM
Antibody Engineering
Room: Colorado Ballroom

Speaker 1 of 6
* James A. Ernst, Genentech, Inc., USA

Monday, April 08 | 5:00PM - 7:00PM
Antibody Engineering
Room: Colorado Ballroom

Speaker 2 of 6
Janine Schuurman, Genmab B.V., Netherlands
Engineering Non-Classical Antibody Formats Inspired by Nature

Monday, April 08 | 5:00PM - 7:00PM
Antibody Engineering
Room: Colorado Ballroom

Speaker 3 of 6
Feng Wang, Chinese Academy of Sciences, China
A Tumor Targeted Immune Checkpoint Blocker

Monday, April 08 | 5:00PM - 7:00PM
Antibody Engineering
Room: Colorado Ballroom

Speaker 4 of 6
Germaine Fuh, 23andMe, Inc., USA
Engineering Antibody Specificity and Stability Using Deep Sequencing

Monday, April 08 | 5:00PM - 7:00PM
Antibody Engineering
Room: Colorado Ballroom

Speaker 5 of 6
Aliza Borenstein-Katz, Weizmann Institute, Israel
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker

Monday, April 08 | 5:00PM - 7:00PM
Antibody Engineering
Room: Colorado Ballroom

Speaker 6 of 6
Chia Yin Lee, Singapore Immunology Network, Singapore
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine

Monday, April 08 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Monday, April 08 | 7:30PM - 10:00PM
Poster Session 1
Room: Breckenridge Ballroom


Tuesday, April 09 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 1 of 9
* Andreas G. Plückthun, University of Zürich, Switzerland

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 2 of 9
Nai-Kong V. Cheung, Memorial Sloan-Kettering Cancer Center, USA
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 3 of 9
Christian Klein, Roche, Switzerland
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom


Coffee Break

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 5 of 9
John R. Desjarlais, Xencor, Inc., USA
Bispecific Antibodies for T Cell Recruitment and T Cell Activation

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 6 of 9
Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Next-Generation Chimeric Antigen Receptors

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 7 of 9
Udaya S Rangaswamy, Teneobio, USA
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell-Mediated Killing of Tumor Cells with Minimal Cytokine Release

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 8 of 9
Lina Bartels, AIMM Therapeutics & Amsterdam University Medical Center, Netherlands
Short Talk: A T-Cell Engager Based on a Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo without Affecting Normal Hematopoietic Cells

Tuesday, April 09 | 8:00AM - 11:15AM
Bispecific and Engineered Antibodies for Cancer Immunotherap
y

Room: Colorado Ballroom

Speaker 9 of 9
Chad May, Maverick Therapeutics, USA
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody that Regresses Established Solid Tumors in Mice

Tuesday, April 09 | 11:15AM - 5:00PM
On Own for Lunch


Tuesday, April 09 | 11:15AM - 1:00PM
Poster Setup
Room: Breckenridge Ballroom


Tuesday, April 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Breckenridge Ballroom


Tuesday, April 09 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Tuesday, April 09 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Colorado Ballroom

Speaker 1 of 6
* Christoph Rader, The Scripps Research Institute, USA

Tuesday, April 09 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Colorado Ballroom

Speaker 2 of 6
David D. Ho, Aaron Diamond AIDS Research Center (ADARC), Columbia University Medical Center, USA
A Bispecific Antibody, 10E8.4/iMab, for HIV Therapy and Prevention

Tuesday, April 09 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Colorado Ballroom

Speaker 3 of 6
JoAnn A. Suzich, AstraZeneca, USA
Antibodies for the Prevention and Treatment of Viral Infections

Tuesday, April 09 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Colorado Ballroom

Speaker 4 of 6
Kartik Chandran, Albert Einstein College of Medicine, USA
Development of Engineered and Natural Antibodies as Anti-Ebola Therapeutics

Tuesday, April 09 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Colorado Ballroom

Speaker 5 of 6
Sisi Shan, Tsinghua University, China
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus

Tuesday, April 09 | 5:00PM - 7:00PM
Antibodies for Infectious Diseases
Room: Colorado Ballroom

Speaker 6 of 6
Anna Zumsteg, Regeneron Pharmaceuticals, USA
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive
Disease


Tuesday, April 09 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Tuesday, April 09 | 7:30PM - 10:00PM
Poster Session 2
Room: Breckenridge Ballroom


Wednesday, April 10 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 1 of 9
* Germaine Fuh, 23andMe, Inc., USA

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 2 of 9
Ronit Mazor, MedImmune, USA
Immunogenicity of Recombinant Immunotoxins and Approaches to Mitigate It

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 3 of 9
Kerry Culm-Merdek, ImmunoGen, USA
Optimizing the Activity of Antibody Drug Conjugates

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom


Coffee Break

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 5 of 9
John M. Lambert, USA
Site-Specific Conjugation in ADC Design: Panacea or Hype? Lessons from a Case Study with a Maytansinoid Conjugate

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 6 of 9
W. Michael Kavanaugh, Cytomx Therapeutics, USA
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 7 of 9
Armine Matevossian, Novartis Institutes for BioMedical Research, USA
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions
by the Antibody Component of the Drug


Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 8 of 9
Bradley Pearse, Magenta Therapeutics, USA
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients

Wednesday, April 10 | 8:00AM - 11:15AM
Antibody Drug Conjugates
Room: Colorado Ballroom

Speaker 9 of 9
Brian H. Santich, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Self-Assembling and Disssembling (SADA) Bispecific Antibodies (BsAb) for 2-Step Pretargeted RadioImmunotherapy (PRIT)

Wednesday, April 10 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, April 10 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Wednesday, April 10 | 5:00PM - 7:00PM
Delivering Antibodies into the Brain
Room: Colorado Ballroom

Speaker 1 of 6
* Jennifer R. Cochran, Stanford University, USA

Wednesday, April 10 | 5:00PM - 7:00PM
Delivering Antibodies into the Brain
Room: Colorado Ballroom

Speaker 2 of 6
Joy Yu Zuchero, Denali Therapeutics Inc, USA
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach


Wednesday, April 10 | 5:00PM - 7:00PM
Delivering Antibodies into the Brain
Room: Colorado Ballroom

Speaker 3 of 6
Per-Ola Freskgard, Roche Innovation Center Basel, Switzerland
Crossing the Blood-Brain Barrier with Antibodies to Access Brain Targets

Wednesday, April 10 | 5:00PM - 7:00PM
Delivering Antibodies into the Brain
Room: Colorado Ballroom

Speaker 4 of 6
Allan Jensen, Lundbeck, Denmark
Antibody-Based Therapies for Neurodegenerative Diseases

Wednesday, April 10 | 5:00PM - 7:00PM
Delivering Antibodies into the Brain
Room: Colorado Ballroom

Speaker 5 of 6
Mathieu Oosterlaken, Institut de Génomique Fonctionelle, France
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain

Wednesday, April 10 | 5:00PM - 7:00PM
Delivering Antibodies into the Brain
Room: Colorado Ballroom

Speaker 6 of 6
Chiara Figazzolo, University of Cambridge, UK
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aß42 Peptide

Wednesday, April 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, April 11 | 7:00AM - 8:00AM
Breakfast
Room: Summit Gallery


Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 1 of 8
* Christian Klein, Roche, Switzerland

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 2 of 8
Christoph Rader, The Scripps Research Institute, USA
Chemically Programmed Bispecific Antibodies

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 3 of 8
James A. Ernst, Genentech, Inc., USA
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom


Coffee Break

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 5 of 8
Andreas G. Plückthun, University of Zürich, Switzerland
Engineering DARPins for Delivery into Cells

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 6 of 8
Krzysztof Masternak, NovImmune SA, Switzerland
Bispecific CD47 Antibodies for Treatment of Cancer

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 7 of 8
Peter J. Hudson, Avipep Pty Ltd, Australia
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases

Thursday, April 11 | 8:00AM - 11:00AM
Bispecific Antibodies and Antibody Like Molecules
Room: Colorado Ballroom

Speaker 8 of 8
Leandrew A. Dailey, Albert Einstein College of Medicine, USA
Short Talk: Engineering Next-Generation Bispecific Antibodies against Filoviruses

Thursday, April 11 | 11:00AM - 5:00PM
On Own for Lunch


Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 1 of 7
* Mark S. Cragg, University of Southampton, UK

Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 2 of 7
Nicole Piché-Nicholas, Pfizer, USA
Changes in Complementarity-Determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics

Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 3 of 7
Trevor RF Smith, Inovio, USA
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)

Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 4 of 7
Olivia Vergnolle, Albert Einstein College of Medicine, USA
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement

Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 5 of 7
Masahiro Yasunaga, National Cancer Center, Japan
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging

Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 6 of 7
Henry Wilson, The Scripps Research Institute, USA
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries

Thursday, April 11 | 2:30PM - 4:30PM
Workshop 2: Antibodies for Immunological Applications
Room: Colorado Ballroom

Speaker 7 of 7
Gregory Mann, École Polytechnique Fédérale de Lausanne, Switzerland
Using Monobodies to Target Cytoplasmic Oncoproteins

Thursday, April 11 | 4:30PM - 5:00PM
Coffee Available
Room: Colorado Ballroom Foyer


Thursday, April 11 | 5:00PM - 6:45PM
Beyond Checkpoint Blockade: Novel Approaches for Immunothera
py

Room: Colorado Ballroom

Speaker 1 of 5
* Mark S. Cragg, University of Southampton, UK

Thursday, April 11 | 5:00PM - 6:45PM
Beyond Checkpoint Blockade: Novel Approaches for Immunothera
py

Room: Colorado Ballroom

Speaker 2 of 5
Mikael C. I. Karlsson, Karolinska Institutet, Sweden
Anti-Marco Antibodies in Tumor Immunotherapy

Thursday, April 11 | 5:00PM - 6:45PM
Beyond Checkpoint Blockade: Novel Approaches for Immunothera
py

Room: Colorado Ballroom

Speaker 3 of 5
Sean Hua Lim, University of Southampton, UK
Optimizing Anti-Tumor Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists

Thursday, April 11 | 5:00PM - 6:45PM
Beyond Checkpoint Blockade: Novel Approaches for Immunothera
py

Room: Colorado Ballroom

Speaker 4 of 5
Sapna Yadavilli, GlaxoSmithKline, USA
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody

Thursday, April 11 | 5:00PM - 6:45PM
Beyond Checkpoint Blockade: Novel Approaches for Immunothera
py

Room: Colorado Ballroom

Speaker 5 of 5
Wen Jie Chin, Agency for Science, Technology and Research, Singapore
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells

Thursday, April 11 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Colorado Ballroom


Thursday, April 11 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Breckenridge Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, April 11 | 8:00PM - 11:00PM
Entertainment
Room: Breckenridge Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, April 11 | 8:00PM - 11:00PM
Cash Bar
Room: Breckenridge Ballroom


Friday, April 12 | 10:24AM - 10:24AM
Departure


*Session Chair.